Technology
Health
Biotechnology

Denali Therapeutics

$20.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.05%) As of 2:06 PM EDT today
-$0.01 (-0.05%) Today

Why Robinhood?

You can buy or sell DNLI and other stocks, options, ETFs, and crypto commission-free!

About DNLI

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Read More Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

CEO
Employees
179
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.91B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
430.67K
High Today
$20.11
Low Today
$19.71
Open Price
$20.07
Volume
80.15K
52 Week High
$28.87
52 Week Low
$12.32

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2017 IPO
US

DNLI Earnings

-$0.59
-$0.13
$0.33
$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.